Themes US R&D Champions ETF (USRD) is an exchange-traded fund that seeks to provide investment results corresponding to the performance of the Themes US R&D Champions Index, focusing on U.S. companies demonstrating high research and development (R&D) spending relative to revenue. The ETF offers exposure to innovative firms across sectors such as technology, healthcare, and consumer discretionary; it tracks a rules-based index selecting companies with R&D intensity above a specified threshold, weighted by market capitalization and R&D metrics. USRD primarily serves institutional and retail investors targeting growth-oriented equities driven by innovation.
The fund operates exclusively in the U.S. equity market, with holdings concentrated in domestic large- and mid-cap companies; it was launched in 2023 and is headquartered in New York, New York, under the management of a prominent ETF provider specializing in thematic strategies. Geographically, its portfolio companies conduct operations primarily within the United States, though some have global reach through subsidiaries.
In recent developments, USRD expanded its index methodology in mid-2025 to incorporate forward-looking R&D pipeline data, enhancing selection criteria for biotech and AI firms; the fund also announced a strategic partnership with a leading data analytics firm to refine R&D scoring algorithms. Assets under management grew significantly following a 2024 seed funding round from venture capital backers focused on innovation themes, reaching over $500 million by late 2025. No major acquisitions or reorganizations have occurred, but the ETF introduced a dividend reinvestment option in early 2025 to attract income-focused investors.